

Date: 16th July, 2022

To,

BSE Limited

P. J. Towers, Dalal Street, Fort,

Mumbai – 400 001

To,

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,

Bandra (East), Mumbai-400 051

Ref.: BSE Scrip Code No. "533138" **Ref.:** "ASTEC"

Sub.: Statement of Investor Complaints as per Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 30th June, 2022

Dear Sir,

Please find enclosed herewith, Statement of Investor Complaints as per Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 30th June, 2022.

Please take the same on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan Company Secretary & Compliance Officer (FCS 7167)

Encl.: A/a









Statement of Investor Complaints pursuant to Regulation 13(3) of the

<u>Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)</u> Regulations, 2015 for the Quarter ended 30th June, 2022

Name of Company: Astec LifeSciences Limited

Scrip Code/Scrip name: BSE – 533138

NSE – ASTEC

Investor Complaints	Quarter ended 30 th June, 2022
Pending at the beginning of the Quarter	0
Received during the Quarter	0
Disposed off during the Quarter	0
Remaining unresolved at the end of the Quarter	0

For Astec LifeSciences Limited

Tejashree Pradhan Company Secretary & Compliance Officer (FCS 7167)







